# Phase 1 Lymphoma, B-Cell trials recruiting: 67 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 67 trials in phase 1 for Lymphoma, B-Cell that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Lymphoma, B-Cell trials: 67 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/lymphoma-b-cell

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 67
- Recruiting or not yet: 67
- Read on: November 19, 2026

## Trials

The 25 newest of 67, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 2, 2026 | NCT07910708 | GN001 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia | Department of Hematology,Rheumatology and Immunology,Pu'er People's Hospital | Phase 1 | Recruiting | Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07910708) |
| October 13, 2026 | NCT07871747 | Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART) | University of Chicago | Phase 1 | Not yet recruiting | Lymphoma, B-Cell, Multiple Myeloma | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871747) |
| August 20, 2026 | NCT07775508 | In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma | Chinese PLA General Hospital | Phase 1 | Recruiting | B-cell Lymphoma | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07775508) |
| July 9, 2026 | NCT07691606 | A Study of ARC-02 in B-cell NHL | Taiho Oncology, Inc. | Phase 1 | Recruiting | B-cell Non Hodgkin Lymphoma | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07691606) |
| June 22, 2026 | NCT07661537 | A Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 | Recruiting | B-cell Non-Hodgkin Lymphoma | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07661537) |
| May 29, 2026 | NCT07616089 | Phase I Study of FXS0683 in the Treatment of Blood Tumors | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 1 | Recruiting | B-Cell Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia | 228 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07616089) |
| April 20, 2026 | NCT07539688 | Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell Lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 | Not yet recruiting | Relapsed/Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma, Inert B-cell Lymphoma Transformed Into Large B-cell... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07539688) |
| April 16, 2026 | NCT07532525 | Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma | University of Michigan Rogel Cancer Center | Phase 1 | Recruiting | Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07532525) |
| March 5, 2026 | NCT07451054 | CD45BE-HSPC + CART-45 Cells | University of Pennsylvania | Phase 1 | Recruiting | B-Cell Non-Hodgkin Lymphoma (NHL), Richter's Transformation, T-Cell Non-Hodgkin Lymphoma, Hodgkin Lymphoma | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07451054) |
| February 10, 2026 | NCT07398963 | Clinical Study of Oncolytic Vaccinia VIrus Delivering Targeted CD19 in Vivo CAR-T/M Therapy for Refractory/Relapsed B-cell Lymphoma | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 1 | Recruiting | Refractory/Relapsed B-cell Lymphoma | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07398963) |
| January 27, 2026 | NCT07369492 | Safety and Efficacy Study of BAFF-R CAR-T Cells in Adult Subjects With CD19-Negative Relapsed or Refractory B-Cell Lymphoma | Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | B-cell Lymphoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07369492) |
| January 26, 2026 | NCT07367685 | Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma | The Second Affiliated Hospital of Fujian Medical University | Phase 1 | Not yet recruiting | Recurrent/Refractory B-cell Lymphoma | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07367685) |
| January 13, 2026 | NCT07335328 | Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies | Medical College of Wisconsin | Phase 1 | Not yet recruiting | B-cell Non Hodgkin Lymphoma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07335328) |
| January 12, 2026 | NCT07334574 | Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL | Ruijin Hospital | Phase 1 | Not yet recruiting | B-cell Non-Hodgkin's Lymphoma (B-NHL) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07334574) |
| January 5, 2026 | NCT07316920 | A Clinical Study of of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Relapsed/Refractory B-cell Lymphoma | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07316920) |
| November 20, 2025 | NCT07239323 | In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma, Multiple Myeloma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07239323) |
| November 18, 2025 | NCT07234045 | A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 | Not yet recruiting | Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, Relapsed/Refractory B-cell ALL | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07234045) |
| November 6, 2025 | NCT07225439 | Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin... | Sponsor not shown (see the record) | Phase 1 | Recruiting | Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary... | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07225439) |
| September 10, 2025 | NCT07166549 | Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial) | University Hospital, Basel, Switzerland | Phase 1 | Not yet recruiting | B Cell Malignancies, B-cell Leukemia, B Cell Lymphoma, Bispecific Chimeric Antigen Receptor (CAR) T Cells, Relapsed or... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07166549) |
| August 3, 2025 | NCT07101328 | A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF\_FRontier-1 ) | Eli Lilly and Company | Phase 1 | Recruiting | Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, B-cell... | 215 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07101328) |
| July 30, 2025 | NCT07093073 | Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Phase 1 | Recruiting | B Cell Lymphoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07093073) |
| July 18, 2025 | NCT07073833 | The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma | Imbioray (Hangzhou) Biomedicine Co., Ltd. | Phase 1 | Recruiting | Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07073833) |
| July 18, 2025 | NCT07072169 | A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) | Ruijin Hospital | Phase 1 | Recruiting | B-cell Non-Hodgkin Lymphoma | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07072169) |
| July 16, 2025 | NCT07068906 | A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 | Not yet recruiting | B-Cell Non-Hodgkin Lymphoma | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07068906) |
| July 8, 2025 | NCT07053670 | A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 ) | Tongji Hospital | Phase 1 | Recruiting | B-Cell Non-Hodgkin Lymphoma | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07053670) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Mayo Clinic | 3 |
| Institute of Hematology & Blood Diseases Hospital, China | 3 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 3 |
| [Chongqing Precision Biotech Co., Ltd](https://specstream.ai/data/clinical-trials/company/chongqing-precision-biotech-co-ltd) | 2 |
| National Cancer Institute (NCI) | 2 |
| Peking University Cancer Hospital & Institute | 2 |
| [Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.](https://specstream.ai/data/clinical-trials/company/shanghai-fosun-pharmaceutical-industrial-development-co-ltd) | 2 |
| City of Hope Medical Center | 2 |
| Guangdong Ruishun Biotech Co., Ltd | 2 |
| Ruijin Hospital | 2 |
| MSD R&D (China) Co., Ltd. | 1 |
| Department of Hematology,Rheumatology and Immunology,Pu'er People's Hospital | 1 |
| The Third Affiliated Hospital of Southern Medical University | 1 |
| Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | 1 |
| Umoja Biopharma | 1 |
| University of Colorado, Denver | 1 |
| Therapeutic Advances in Childhood Leukemia Consortium | 1 |
| The Second Affiliated Hospital of Fujian Medical University | 1 |
| University of Chicago | 1 |
| Guangzhou Lupeng Pharmaceutical Company LTD. | 1 |
| PeproMene Bio, Inc. | 1 |
| Autolus Limited | 1 |
| [Suzhou Suncadia Biopharmaceuticals Co., Ltd.](https://specstream.ai/data/clinical-trials/company/suzhou-suncadia-biopharmaceuticals-co-ltd) | 1 |
| Tongji Hospital | 1 |
| M.D. Anderson Cancer Center | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 34 |
| United States | 26 |
| Australia | 7 |
| Spain | 5 |
| Canada | 4 |
| Denmark | 3 |
| Italy | 3 |
| United Kingdom | 2 |
| Serbia | 2 |
| South Korea | 2 |
| France | 2 |
| Poland | 2 |
| Singapore | 1 |
| Taiwan | 1 |
| Switzerland | 1 |
| Sweden | 1 |
| Germany | 1 |
| Japan | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Landscape architecture firms in the United States](https://specstream.ai/data/businesses/landscape-architecture-firms/united-states)
- [Trucking companies in the United States](https://specstream.ai/data/businesses/trucking-companies/united-states)
- [Electric utilities in the United States](https://specstream.ai/data/businesses/electric-utilities/united-states)
- [Pediatric pulmonology practices in the United States](https://specstream.ai/data/businesses/pediatric-pulmonology-practices/united-states)
- [B2B mining companies in the United States](https://specstream.ai/data/businesses/b2b-mining-companies/united-states)
- [Hong Kong style cafes in the United States](https://specstream.ai/data/businesses/hong-kong-style-cafes/united-states)
